On a sad note, EVI brings news of the death of Dr Egeruan Babatunde Imoukuede. Tunde, as he was known to his friends, joined EVI in 2005 as Clinical and Regulatory Affairs Director. He left in 2013 to work for the Jenner Institute at University of Oxford. Babatunde was a brilliant advocate for the battle against diseases of poverty. During all the years he was fighting for his life, he was an example of resilience and professionalism. He will be remembered at EVI for his persistent committment to research and development of malaria vaccines.
ExpreS2ion Biotech announces the second successful evaluation of safety by the independent safety monitoring board for the phase Ia clinical trial of the placental malaria vaccine candidate, PAMVAC. Due to the trial’s staggered approach, the second evaluation allows initiation of the phase Ib clinical trial to be conducted in Benin, Africa. The clinical trial is funded by the EU under the FP7 program and coordinated by associate professor Morten A Nielsen at University of Copenhagen in collaboration with University of Tübingen, Université d'Abomey-Calavi, European Vaccine Initiative, Institut de Recherche pour le Développement, and ExpreS2ion Biotech.
This year’s Sofja Kovalevskaja awardees have been anounced. Dr. Faith Osier (Kenya Medical Research Institute (KEMRI), Kilifi) is among them. Her project in the Parasitology Department at the UniversitätsKlinikum Heidelberg will commence in November 2016. For further information on the laureates see Humboldt homepage
This year’s BELLEROPHON annual meeting took place 07-08 July in Heidelberg, Germany. Staying at the ‘Internationales Wissenschaftsforum’ in the old town of Heidelberg allowed the participants to discuss the scientific progress in a charming and pleasant atmosphere.
The Japanese Global Health Innovative Technology Fund (GHIT) has produced two short videos https://youtu.be/Nq6u_cCzn4k and https://youtu.be/dtZPEBG9ljM shot on location in Uganda, South East Asia and Burkina Faso, the latter being where the SEmalvac project, funded by GHIT, is ongoing. The main objective is to assess the safety and immunogenicity of the recombinant Escherichia coli BK-SE36 malaria vaccine candidate in healthy malaria exposed African children. GHIT support also aims to improve maternal health and child survival through innovative means and strategies. Health improvement will secure well being and productivity. These two movies stress the need to maintain a sustainable partnership.
The Global Health Innovative Technology Fund (GHIT) annual partners meeting was held on 7 June at Roppongi, Japan.
Prof Toshi Horii and Dr Sodiomon Sirima gave presentations in session 1 "innovation and impact".
The European & Developing Countries Clinical Trials' Partnership (EDCTP) invites nominations to the following awards: Scientific Leadership Award, Outstanding Female Scientist Award and Outstanding Research Team Award.
Congratulations to Thorsten Kohaut, whose well deserved promotion to Chief Financial Officer came into effect on 1 May 2016.
EVI extends a warm welcome to two new team members. Hilde Depraetere joined EVI on 1 July as Senior Project Manager, and yesterday 6 July Leah Williams commenced duties as Programme Manager Assistant.
The second EDUFLUVAC workshop on experimental animal models for universal influenza vaccines took place on 23-24 June 2016 at the Biomedical Primate Research Centre, Rijswijk, The Netherlands. The workshop was organised by EDUFLUVAC, EU - Framework programme 7 funded project with the financial support of Sanofi Pasteur and Viroclinics.